ANNOUNCEMENTS AND PRESS RELEASES

Responsible AI – The Application of Advanced AI in Pharmacovigilance

May 13, 2024 - San Ramon, CA

Arietta.ai, a leader in life sciences Applied AI solutions, is presenting at the Pharmacovigilance Europe 2024: The 11th Annual International Conference And Exhibition In Pharmacovigilance, Regulatory Affairs, Risk Management And Clinical Trials in London, UK on May 15, 2024. Tim Howard, CEO of Arietta.ai, will discuss responsible application in pharmacovigilance. His presentation will explore the multiple dimensions of responsibility that must be considered for successful AI adoption by drug safety teams.

“Patient, pharmacovigilance staff, and regulator perspectives must be integrated into an expanded definition of what Responsible AI adoption means when it comes to drug safety. An inclusive approach sets the foundation for near and long term success and acceptance of applied Ai solutions,” commented Tim Howard. "Superior large language model based extraction and classification must be coupled with a robust security architecture providing full transparency and accountability."

The presentation and discussion will address the importance of considering patient privacy, the impact on staff responsibilities, regulatory requirements, and how they must be inherent in AI solutions. Tim will join other leaders in pharmacovigilance and technology to discuss the ongoing challenges in drug safety data management, analysis, signal detection, and reporting.

For further inquiries or to schedule a meeting, contact us here: https://www.arietta.ai/#contact. Additional information about the conference including registration can be found at https://pveurope.com/.

Adopting AI-Driven Automation in Pharmacovigilance AND Achieving a Compelling ROI

May 1, 2024 - San Ramon, CA

Arietta.ai, a leader in life science Applied AI solutions, is slated to present at the 35th Pharmacovigilance 2024 Conference in Boston, MA on May 3, 2024. Tim Howard, CEO of Arietta.ai, will delve into the pivotal role accelerated ROI plays in achieving a successful initial rollout of advanced AI by pharmacovigilance departments.

"Adapting to executives' expectations regarding AI adoption is pivotal for strategic alignment within organizations. By approaching Applied AI integration in drug safety with a focused lens, we can achieve significant process enhancements while realizing a significant ROI within 12 months," commented Tim Howard.

PV leaders are best served by de-emphasizing the transformative potential of Advanced AI and focusing on the pragmatic benefits of realized time and cost savings and building trust in the underlying AI models. Quick wins that reinforce AI’s role to assist, and not replace, medical experts establish a foundation for long term success and innovation.

"The adoption of LucidPV as an Applied AI point solution for pharmacovigilance supports organizational objectives and provides tangible evidence of the profound impact focused AI solutions can have on overall business success," remarked James Brooks, Chairman of Arietta.ai.

Tim joins other pharmacovigilance and technology leaders to discuss prevalent challenges in drug safety data collection, analysis, signal detection, and reporting. The event provides a valuable platform for networking, knowledge exchange, and professional development.

Tim's presentation is scheduled for Friday, May 3rd, at 9:40 am, followed by a Q&A session and networking opportunities. For further inquiries or to schedule a meeting, contact us here: https://www.arietta.ai/#contact. Additional details about the conference are available at https://usa-canada.virtueinsight.com/event/pharmacovigilance/.

LucidPV v24.0 Release Achieves General Availability

April 30, 2024 - San Ramon, CA

LucidPV, the industry’s most advanced LLM-based AI product for Pharmacovigilance intake and triage, today achieved general availability of v24.0. The new version of LucidPV adds significant advancements that solve for more challenges that safety teams face with an increasingly complex range of sources, formats, content, and seriousness levels of adverse event reports. In response to customer feedback, LucidPV v24.0 adds 113 key enhancements and features including capabilities such as: automated translation of adverse event reports from more than 70 languages, AI-powered automated Initial/Follow-up/Duplicate classification, and Literature Abstract extraction and classification. Customer benefits of LucidPV include:

• ROI amplification: Increases the impact, speed, and effectiveness of current teams, systems, and processes

• Seamless automation: Accelerates case receipt, triage, and book-in without disruption to current PV processes

• Reliably fast implementation: Can be up and running in a matter of weeks, not months or years

• Full control and visibility: Better transparency and measurability of all PV performance, trends, and bottlenecks

• Continuous learning: Incorporates user feedback, new data, and new technology to learn and improve over time

“This kind of rapid advancement is what PV teams need to keep pace with demands. The latest version of LucidPV delivers a fast ROI by saving customers time and improving quality within their patient safety operations,” said Nick Hermann, Arietta’s Chief Customer Officer. “Having supported many customers through implementations, I’m excited how LucidPV can be stood up quickly with our out-of-the-box pre-trained AI.”

“We continue to take an AI-first approach to designing and developing LucidPV v24.0. This enables us to build responsible AI solutions that are elegant, fast and easy for customers to integrate into their existing workflow and systems,” said Mike Weber, Arietta’s Chief Product Officer.

LucidPV v24.0 is available now to organizations who are looking to leverage AI and large language models to automate their patient safety processes without impacting their current investments in existing technology. Trial versions are also available. To request more information please contact Arietta.ai here: https://www.arietta.ai/#contact

Arietta.ai Expands Commercial Team

February 20, 2024 - San Ramon, CA

Arietta.ai, an innovation leader in healthcare AI solutions, today announced expansion of its commercial team to support demand for its solutions offering more efficient and accurate AI for patient safety.

Brittany Griffin recently joined the Arietta.ai team as Director of Revenue Operations. She brings with her a unique background in Life Sciences and SaaS, having worked across technology, biotech and directly in pharma. With over a decade of experience, Brittany has extensive knowledge within Revenue Operations, Sales and Customer Success, and has leveraged her skills to help organizations scale effectively and efficiently. With a personal passion for opportunities at the intersection of healthcare and technology, Brittany is poised to play an important role in Arietta.ai’s rapid growth, driven by the great response received to the launch of LucidPV.

LucidPV v23.0 Release Achieves General Availability

December 5, 2023 - San Ramon, CA

Arietta.ai, a leader in life sciences applied AI solutions, has now made v23.0 of its flagship product LucidPV generally available. LucidPV v23.0 includes 178 features and enhancements focused on bringing a new level of LLM-based AI automation, quality, and performance to the intake and triage workflows of safety teams. Safety teams are now able to achieve a new level of efficiency and performance via the following benefits:

• Time savings: Accelerated case book-in and non-case filtering with streamlined extraction review

• Speed to value: Rapid and easy connection to existing process to be up and running within one month

• Force multiplier: Augments impact of safety teams and systems, freeing the team to focus on higher value activities

• Continuous improvement: Systems and AI learn and improve over time, while shared continuous learning results in accelerated improvement

• Measurable impact: Transparent and easy to measure ROI with built-in metrics and dashboards

With v23.0 of LucidPV, customers have: pre-trained LLM models for adverse event extraction and classification, unstructured and structured emails and forms automation across a variety of formats, human-in-the-loop oversight for full or partial QC checks, E2B file generation and integration to downstream safety systems and processes, comprehensive audit trails and regulatory/compliance certifications.

“The general availability of LucidPV v23.0 represents an important milestone in Arietta.ai’s vision to be the driving force behind how the Life Sciences industry embraces AI responsibly,” said Tim Howard, CEO of Arietta.ai. “We and the industry are ready to become more efficient, cost effective, accurate, and timely in how we understand and respond to adverse events and other forms of feedback from patients, providers, caregivers, and regulators.”

To request more information please contact Arietta.ai here: https://www.arietta.ai/#contact

Arietta.ai Launches Artificial Intelligence Platform to Accelerate Insights in Life Sciences

September 26, 2023 - San Ramon, CA

Arietta.ai, a pioneering force in healthcare AI solutions, today announced the official launch of its revolutionary artificial intelligence platform designed to expedite safety and pharmacovigilance case processing for life science companies. Led by a seasoned team of life sciences experts and powered by purpose-built and expressly trained large language models, Arietta.ai aims to transform the industry by enabling the swift processing, analysis, and extraction of valuable insights from incoming product communications.

"True to our name, we are committed to delivering focused, elegant solutions that showcase innovative brilliance,” said Tim Howard, President & CEO of Arietta.ai. “Responsible AI is our guiding principle, underscoring the importance of accommodating a trained 'person-in-the-middle' as trust in the system is nurtured and models evolve, learn, and improve. Our focus is on empowering organizations with advanced time-saving tools that enhance the capabilities of medical experts. We recognize the benefits of speed and quality in healthcare, and our solutions are specifically engineered to expedite processes."

Arietta.ai's first solution, to be introduced on October 4th at the World Drug Safety Congress in Amsterdam and Boston, addresses the critical challenges faced by drug safety departments across the life science sector. This offering streamlines adverse event intake and triage, enabling timely, accurate, consistent, and compliant case processing. The use of purpose-built and expressly trained large language models delivers unmatched extraction and classification performance, providing pharmacovigilance departments substantial time, resource savings and ultimately safety performance.

“Arietta.ai exemplifies how exceptional management teams can accelerate disruptive solutions for unmet business needs,” said James Brooks, Chairman of Arietta.ai. “Our easy-to-implement solution leverages AI to solve immediate, tangible business problems that reduce costs.”

“We are excited to debut Arietta’s first market offering at the World Drug Safety Congresses,” added Mike Weber, Arietta's Chief Product Officer. “We will be showcasing live product demonstrations that highlight how Arietta's solution can dramatically expedite data extraction and classification processes for the pharmacovigilance market."

Arietta.ai is based in Northern California, the global hub for artificial intelligence development, with teams in San Francisco and London to serve its global client base. The company has substantial private backing from individuals with a successful track record of investments in life sciences services and technology. The Arietta.ai team is led by Tim Howard, a seasoned life sciences executive with more than two decades of experience. The company's leadership team features talent from industry innovators such as Veeva, Salesforce, Accenture, Thompson Reuters, and Hewlett Packard.

———————————————————-

About Arietta.ai

Arietta.AI is the driving force behind safer and more efficient healthcare AI solutions. Through the strategic delivery of advanced AI technologies, we aim to elevate medical decision-making and performance insights to new heights, all while ensuring substantial time savings. We aim to pave the way to become the trusted and proven AI innovation partner for our healthcare clients, and together build a healthier world, where data and innovation converge to safeguard lives and create a meaningful impact on global healthcare. To learn more visit www.arietta.ai.

Media Contact

Mike Weber
media@arietta.ai